Search - tctmd.com

Displaying 901 - 920 of 2311

Sort: Relevancy | Date

Impact of Preexisting and New-Onset A-fib on TAVR Outcomes

Presentation

Impact of Preexisting and New-Onset A-fib on TAVR Outcomes

October 18, 2019

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

News Daily News

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

October 18, 2019

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

News Conference News TCT 2019

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

October 09, 2019

Presentation TCT Abstracts Posters 2019

Non-ST Elevation Myocardial Infarction in Hospitalized Patients With Atrial Fibrillation

Presenter: Pengyang Li

October 05, 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

News Conference News TCT 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

October 04, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

Presentation TCT Abstracts Posters 2019

In-hospital Outcomes of Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation: Nationwide Database Analysis

Presenter: Fangcheng Wu

September 29, 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

News Conference News TCT 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Yael L. Maxwell

September 29, 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

September 29, 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

News Conference News TCT 2019

Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis

Michael O'Riordan

September 27, 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presentation TCT 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presenter: Teresa Carman

September 27, 2019

When and How to Switch to OAC Alone After PCI?

Presentation TCT 2019

When and How to Switch to OAC Alone After PCI?

Presenter: Manesh Patel

September 27, 2019

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Presentation TCT 2019

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Presenter: Dominick Angiolillo

September 27, 2019

PCI in Patients Requiring OAC: Which OAC and in Whom?

Presentation TCT 2019

PCI in Patients Requiring OAC: Which OAC and in Whom?

Presenter: Davide Capodanno

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presentation TCT 2019

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presenter: Robert Byrne

September 27, 2019

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Presentation TCT 2019

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Presenter: Fabian Nietlispach

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.